Brain Metastasis in Patients with Neuroendocrine Neoplasia of Gastroenteropancreatic Origin: A Single Centre Experience Abstract #2937

Introduction: Brain metastasis (BrMet) in patients (pts) with neuroendocrine neoplasia (NEN) of gastroenteropancreatic (GEP) origin is extremely rare. Data on management and outcome are limited.
Aim(s): We aim to describe the features and outcome of such pts from our PRRT cohort.
Materials and methods: Retrospective review of pts with GEP NEN diagnosed with BrMet identified from cancer imaging database.
Conference: 17th Annual ENETS Conference (2020)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Javad Saghebi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#87 Alterations of E-cadherin, beta-catenin and caveolin-1 expression in gastroenteropancreatic neuroendocrine tumors
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP NETs) comprise a heterogeneous group of neoplasm with different histological patterns and biological behavior. Only limited information is available on immunohistochemical prognostic factors of disease. Alterations in the cell-cell adhesion system are closely associated with cell invasion and metastasis in many malignancies, including those of endocrine origin. Abnormal expression of E-cadherin and beta-catenin has been reported to play an important role in these processes. Caveolin-1 has recently been identified as a tumor metastasis modifier factor, which might increase the cell metastasis potential through the interaction with E-cadherin. However, the role of caveolin-1 in GEP NETs cell invasion remains unknown.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Vera V Delektorskaya
#1391 Favourable responses in Patients with Bulky Neuroendocrine Tumours (NET) - A Personalised Approach Using 90Y-DOTA-Octreotate Sequenced with 177Lu-DOTA-Octreotate Induction Peptide Receptor Chemoradionuclide Therapy (PRCRT)
Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.
Conference: 13th Annual ENETS conference (2016)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Grace Kong
Keywords: PRRT, Y-90
#1630 The Positive Expression of PD-L1/PD-1 in Gastroenteropancreatic Neuroendocrine Neoplasias Correlates with Prognosis
Introduction: The incidence of Neuroendocrine Neoplasias (NENs) is increasing and their pathological characteristics, varied between races. However, the epidemiology of GEP-NENs in Chinese patients remains poorly characterized especially for the expression of important immune checkpoint protein PD1 and PD-L1.
Conference: 14th Annual ENETS conference (2017)
Category: Pathology, grading, staging
Presenting Author: Wu Yinying
Authors: Yinying W, Chuying W, ...
#2153 Brain Metastasis Disclosing Neuroendocrine Tumor
Introduction: A paraganglioma is a rare tumor composed of chromaffin cells. Malignant paraganglioma is a very rare presentation diagnosed by local recurrence after total resection of the primary mass or findings of distant metastasis
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Aicha Bengueddach
#2182 Favourable Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) for Treatment of Metastatic Rectal Neuroendocrine Neoplasia (NEN)
Introduction: Metastatic disease from rectal NEN are less common than other NEN origins, and carries a poor prognosis. Treatment evidence for such patients (pts) is lacking.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Grace Kong
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss out any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team